System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Martin Clodi is an expert in Endocrinology at Convent Hospital of the Brothers of Saint John of God (Austria). As of October 2026, ScienceLeadR ranks Martin Clodi in the top 1% of experts worldwide for Diabetes Mellitus and Glucose Metabolism Disorders. Martin Clodi has authored 199 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 4 of them ongoing. SLR score: 996 (community average: 125). How the SLR is computed.

LeadR Profile

Martin Clodi Convent Hospital of the Brothers of Saint John of God Austria
996 ScienceLeadR Reputation 996

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Internal Medicine - Cardiology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Johannes Kepler University of Linz

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 199

Citations

Citations: 7 350 1st author: 26 Last author: 35 Unique author: 1

Main journals

Wien Klin Wochenschr 63
Eur J Clin Invest 8
Neuroendocrinology 5
Diabetes Care 4
Diabetologia 4

Best Journals

N Engl J Med 3
Lancet Gastroenterol Hepatol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
From Valve Disease to Valve Replacement: Lipoprotein(a) Is Associated with Aortic Stenosis Severity but Not Prognosis After TAVI.
PMID 42646618 — diabetes mellitus, constriction, pathologic, mortality, aortic valve stenosis, lipoproteins, aortic valve, aortic valve disease, transcatheter aortic valve replacement, lipoprotein(a), hemodynamics, prognosis		Med Sci (Basel)20260
Real-world assessment of adherence to inclisiran dosing schedule and LDL-C reduction in patients with hypercholesterolemia in Austria.
PMID 42567787 — cholesterol, ldl, cholesterol, therapeutics, hydroxymethylglutaryl-coa reductase inhibitors, hypercholesterolemia		J Clin Lipidol20260
[Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].
PMID 42461299 — therapeutics		Wien Klin Wochenschr20260
Pneumonia Etiology and Risk Factors in a Tertiary Hospital During the COVID-19 Era: A Retrospective Analysis (2020-2024).
PMID 42443656 — tertiary care centers, comorbidity, mortality, laboratories, internal medicine, hospital mortality, covid-19, pneumonia, obesity, risk factors, obesity paradox		J Gen Intern Med20260
Low-density lipoprotein cholesterol management and goal attainment at 1 year in patients with diabetes, pre-diabetes and normoglycaemia: results from the European, prospective, observational SANTORINI study.
PMID 42373176 — diabetes mellitus, cholesterol, ldl, lipoproteins, cholesterol, therapeutics, lipoproteins, ldl		BMJ Open20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Director: 1

By phase:

Phase 3 14
N/A 8
Phase 2 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 15
Recruiting 4
Unknown 4
Active not recruiting 1
Not yet recruiting 1

By type:

Interventional 21
Observational 4

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 1
multicentricup10 17

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230)
2024-519870-38-00 — safety, cardiovascular diseases		Phase 3Not yet recruiting2026
A randomized double blind placebo controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high risk primary prevention patients (VICTORION 1 PREVENT)
2022-502779-40-00 — cardiovascular diseases, primary prevention		Phase 3Active not recruiting2023
BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The BIO RISK EVENT Study
2024-511950-35-00 — myocardial infarction, risk management, biomarkers, risk factors, heart disease risk factors		Phase 3Recruiting2025
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME CV)
2024-516652-18-00 — cardiovascular diseases, obesity, therapeutics, overweight		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS